At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Multicenter, Randomized, Placebo Controlled, Double Blind Study to Assess the Safety and Efficacy of CC-486 (Oral Azacitidine) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Plus Placebo in Subjects With Previously Treated Locally Advanced or Metastatic Non-small Cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating CC-486, Pembrolizumab, and 1 other intervention for Carcinoma, Non-Small-Cell Lung. Completed, enrolled 100 participants across 33 sites in 6 countries.
Detailed Summary
The purpose of this study is to determine whether the combination therapy of CC-486 (oral azacitidine) and pembrolizumab provides improved patient outcomes compared to pembrolizumab alone in patients with previously treated locally advanced or metastatic non-small cell lung cancer.
Study Details
Timeline
Interventions
CC-486 will be administered orally at a dose of 300 mg daily on days 1-14 of each 21-day cycle.
Pembrolizumab will be administered as a 30-minute IV infusion on day 1 of each 21-day cycle.
Placebo will be administered orally daily on days 1-14 of each 21-day cycle.